SL
GMAB icon

Salomon & Ludwin’s Genmab GMAB Stock Holding History

Salomon & Ludwin’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75K Sell
172
-13
-7% -$345 ﹤0.01% 1839
2026
Q1 		$5.09K Sell
185
-56
-23% -$1.68K ﹤0.01% 1757
2025
Q4 		$7.66K Hold
241
– – ﹤0.01% 1595
2025
Q3 		$8.09K Buy
241
+229
+1,908% +$5.58K ﹤0.01% 1469
2025
Q2 		$245 Buy
+12
New +$246 ﹤0.01% 962
2024
Q4 		– Sell
-31
Closed -$756 – 733
2024
Q3 		$756 Hold
31
– – ﹤0.01% 679
2024
Q2 		$779 Hold
31
– – ﹤0.01% 671
2024
Q1 		$927 Buy
+31
New +$911 ﹤0.01% 781

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Salomon & Ludwin's GMAB Position: Q2 2026 in Review

Salomon & Ludwin reduced its Genmab (GMAB) stake by 7% in Q2 2026, selling an estimated $345 and leaving 172 shares worth $4.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

Salomon & Ludwin first reported a position in GMAB in Q1 2024 and has held it in 8 quarters since. The position peaked at $8.09K in Q3 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Salomon & Ludwin held 172 shares of Genmab worth $4.75K as of Q2 2026.
  • Salomon & Ludwin sold 13 Genmab shares in Q2 2026, an estimated $345.
  • Genmab made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1839 holding.
  • Salomon & Ludwin first reported a position in Genmab in Q1 2024 and has held it in 8 quarters since.
  • Salomon & Ludwin's Genmab position peaked at $8.09K in Q3 2025.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.